Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0780 in Patients With Established ASCVD or at High Risk for a First ASCVD Event
NCT07000357Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic cardiovascular disease (ASCVD) comparing AZD0780 with Placebo (2 arms). Primary endpoint: Time to first event of any component of MACE-PLUS at 54 months. Started Jun 2025; status: recruiting.
02
Drugs
laroprovstat
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT07000357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000357.